Evidence map›Paper›PMID 18294487›Full record

Trial reportAmerican heart journal2008

Outcome in African Americans and other minorities in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).

Judith E Mitchell, Anne S Hellkamp, Daniel B Mark, Jill Anderson, Jeanne E Poole, Kerry L Lee, Gust H Bardy, SCD-HeFT Investigators

Open access · greenAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in American heart journal, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Effectiveness of cardiac resynchronization therapy with defibrillator in at-risk black and white cardiac patients.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2013
    Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Race, ethnicity, and the risk of sudden death<sup/>.Trends in cardiovascular medicine · 2019
    Review
  9. Observational
  10. Observational
  11. Observational
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Judith E MitchellState University of New York Downstate Medical Center, Brooklyn, NY 11203, USA. jemitchell@pol.net
Anne S Hellkamp
Daniel B Mark
Jill Anderson
Jeanne E Poole
Kerry L Lee
Gust H Bardy
SCD-HeFT Investigators
Duke Medical Center · USUniversity of Washington · USClinical Research Institute · USSUNY Downstate Health Sciences University · USThe Seattle Institute for Cardiac Research · US

Funding

SUDDEN CARDIAC DEATH IN HEART FAILURE TRIAL- SCD-HeFTU01HL055766 · NHLBI · UNIVERSITY OF WASHINGTON · PI BARDY, GUST H · 1997 to 2003
$2.0M
NHLBI NIH HHS U01 HL055766
6 · The paper itself

Abstract

backgroundThe SCD-HeFT demonstrated that implantable cardioverter/defibrillator (ICD) therapy significantly improved survival compared to medical therapy alone in stable moderately symptomatic heart failure patients with an ejection fraction < or = 35%. The purpose of this report is to describe the outcomes in African Americans (AAs) and other minorities.

methodsOf 2521 patients enrolled, 23% were minorities and 17% were AAs. Baseline demographic, clinical variables, socioeconomic status, and long-term outcomes were compared according to race. Two major prespecified subgroups were examined: heart failure cause (ischemic vs nonischemic) and New York Heart Association class (II vs III).

resultsAt baseline, compared to whites, AAs were younger and had more nonischemic heart failure, lower ejection fractions, worse New York Heart Association functional class, and higher prevalence of a history of nonsustained ventricular tachycardia. Comparable percentages of whites and AAs held paid jobs, but whites had a significantly higher educational level and household income (P = .001). Compliance with ICD implantation and medical therapy was comparable in both subgroups. No significant difference was observed in the rate of ICD discharge among whites and AAs. Adjusted mortality risk was significantly higher in AAs compared to whites (hazard ratio 1.27, P = .038). Mortality was equally reduced in both race groups receiving ICD therapy compared to placebo (hazard ratio 0.65 in AAs and 0.73 in whites).

conclusionsSurvival benefits from ICD therapy in SCD-HeFT were not dependent on race. In addition, in this clinical trial setting, there was no evidence that AAs were less willing to accept ICD therapy than whites.

Indexed as

Black or African AmericanMinority GroupsAmiodaroneAnti-Arrhythmia AgentsCause of DeathDeath, Sudden, CardiacElectric CountershockFemaleFollow-Up StudiesHeart FailureHumansMaleMiddle AgedPrognosisSurvival RateTime FactorsAmiodaroneAnti-Arrhythmia Agents

Identifiers

PMID18294487
PMCPMC2922509
OpenAlexW2170912922

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.